SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx) / Rugo, Hope S.; Im, Seock-Ah; Wright, Gail Lynn Shaw; Escriva-de-Romani, Santiago; Delaurentiis, Michelino; Cortes, Javier; Bahadur, Shakeela Wazeen; Haley, Barbara B.; Oyola, Raul H.; Riseberg, David A.; Musolino, Antonino; Cardoso, Fatima; Curigliano, Giuseppe; Kaufman, Peter A.; Pegram, Mark D.; Edlich, Sutton; Hong, Sam; Rock, Edwin P.; Gradishar, William John. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 37:15_suppl(2019), pp. 1000-1000. [10.1200/JCO.2019.37.15_suppl.1000]
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)
Musolino, AntoninoConceptualization
;
2019-01-01
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
